| Outcome Measures: |
Primary: Number of Participants With Mean PTH ≤ 300 pg/mL, Number of participants with mean parathyroid hormone (PTH) ≤ 300 pg/mL during the efficacy assessment phase, Efficacy Assessment Phase (weeks 17 to 23) | Secondary: Number of Participants With Mean Ca x P < 55 mg^2/dL^2 and iPTH ≤ 300 pg/mL, Number of participants with mean calcium x phosphorus (Ca x P) \< 55 mg\^2/dL\^2 and intact parathyroid hormone (iPTH) ≤ 300 pg/mL during the efficacy assessment phase, Efficacy Assesment Phase (weeks 17-23)|Number of Participants With Mean Ca x P < 55 mg^2/dL^2, Number of participants with mean calcium x phosphorus (Ca x P) \< 55 mg\^2/dL\^2 during the efficacy assessment phase, Efficacy Assessment Phase (weeks 17 to 23)|Number of Participants With Mean Serum Ca < 9.5 mg/dL, Number of participants with mean serum calcium (Ca) \< 9.5 mg/dL during the efficacy assessment phase, Efficacy Assessment Phase (weeks 17-23)|Number of Participants With Mean Serum P < 5.5 mg/dL, Number of participants with mean serum phosphorus (P) \< 5.5 mg/dL during the efficacy assessment phase, Efficacy Assessment Phase (weeks 17 to 23)
|
